Autopsy report · NCT00382278
Safety Study of Autologous Stem Cell in Liver Cirrhosis
Cause of deathFunding or business
“Other authors showed the same metabolic effect may be obtained when BMMC are delivered peripherally, with lower risk and cost than through hepatic artery.”
Life of this trial
- Registered 10 months after it had already started.
- Ran for about 2 years 3 months before it stopped.
- 15 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Universidade Federal do Rio de Janeiro
- Sponsor type
- University, hospital or other
- Conditions
- Liver Cirrhosis
- Interventions
- Autologous bone marrow-derived mononuclear cells infusion
- Participants
- 15 (planned, not actual)
- Sites
- 1
- Countries
- Brazil
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.